⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Consonance Capital and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Consonance Capital
↗New York, USA
Consonance Capital is a healthcare-focused investment platform based in New York. It operates through two primary entities: Consonance Capital Management, which focuses on long/short public equity investments in the healthcare sector, and Consonance Capital Partners, a private equity firm that invests in lower middle-market healthcare companies.
Founded in 2005, the firm leverages deep industry expertise to partner with management teams across various healthcare sub-sectors, including pharmaceuticals, biotechnology, and healthcare services. They are known for their active, research-driven approach to identifying and supporting growth in life sciences and healthcare enterprises.
CLASSIFICATION
Company Type:Biotech
Therapeutic Areas:
Industry:Pharmaceuticals
Sub-Industry:Healthcare Investment / Private Equity
SIZE & FINANCIALS
Employees:51-200
Founded:2005
Ownership:private
Status:operating
PIPELINE
Stage:Discovery
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Dirigo Therapeutics (collaboration for deprioritized therapeutics)
COMPETITION
Position:Leader
LEADERSHIP
Key Executives:
Mitchell Blutt - CEO and Founder
Kevin Pyun - Partner
LINKS
Website:consonancecapital.com
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Consonance Capital. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.